Innocan Pharma Set to Showcase Innovations at 2025 ThinkEquity Conference

Innocan Pharma Corporation, symbolized as INNO on the Canadian Securities Exchange, is positioning itself at the forefront of the pharmaceutical and biotechnology sectors. Scheduled for October 30, 2025, the company will participate in the highly-anticipated ThinkEquity Conference held at the luxurious Mandarin Oriental in New York City.

The ThinkEquity Conference is a platform renowned for connecting institutional investors, analysts, and emerging growth companies. It promises a day filled with compelling presentations and opportunities for one-on-one meetings, enabling businesses to share their latest updates while discovering new avenues for growth.

Innocan Pharma will take the stage at 9:30 a.m. (New York time) in the Boardroom where key company figures, including CEO Iris Bincovich and COO Roni Kamhi, will provide insightful details about their upcoming regulatory milestones across both human and animal health. A significant focus will be placed on their innovative LPT-CBD injectable platform, which aims to revolutionize chronic pain management.

Joining them will be Dr. Joseph V. Pergolizzi, Jr., M.D., a member of Innocan's distinguished advisory board, whose extensive background in internal medicine and pain management will add significant weight to the presentation. Dr. Pergolizzi comes with a broad experience in pharmacology, drug development, and regulatory affairs, making his insights highly valuable for attendees.

About Innocan's Innovations

Innocan Pharma is pioneering in the pharmaceutical landscape with its unique approach to CBD delivery. The company has developed a cutting-edge CBD-loaded liposome drug delivery platform. This innovative method allows for precise dosing and controlled release of synthetic CBD, aiming to provide effective solutions for pain without relying on opioids.

Moreover, Innocan also has a wellness-focused platform, providing an extensive range of self-care and beauty products designed for a healthier lifestyle. Their commitment to online sales is enhanced through their subsidiary, BI Sky Global Ltd, which aims to leverage advanced digital marketing techniques to reach consumers effectively.

ThinkEquity Conference Overview

ThinkEquity stands out as a boutique investment bank, having facilitated over $50 billion in capital raises, restructurings, and M&As over the years. The conference has become a hallmark event among institutional investors, with previous editions featuring over 70 company presentations and hundreds of one-on-one meetings. This kind of engagement makes it a pivotal moment for companies looking to strengthen their market position and expand their investor base.

As Innocan Pharma gears up for this significant opportunity, their participation signifies a step not only towards enhancing company visibility but also spotlighting their groundbreaking technology in pain management that could redefine patient care.

Conclusion

For anyone interested in the innovative strides Innocan Pharma is making in the pain management sector, and to witness a convergence of industry expertise at the ThinkEquity Conference, detailed insights and updates can be found on their official website at Innocan Pharma.

This is more than just a presentation; it's an invitation to be part of the future of pain management and a healthier lifestyle, showcasing Innocan's commitment to excellence within the pharmaceutical landscape.